Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hope Is Not A Plan: Manufacturing COVID-19 Therapeutics

Executive Summary

Duke-Margolis discussion emphasizes biopharma sector must quickly collaborate on manufacturing coronavirus therapeutics likely to be authorized or approved in coming months.

You may also be interested in...



US DoJ Lets Biotechs Share Manufacturing Details To Speed Launch Of COVID-19 Therapies

Companies are shielded from antitrust concerns by Justice Department as they jointly prepare to manufacture whichever monoclonal-antibody-based coronavirus therapies emerge from development.

Monoclonal Antibodies For COVID-19: Cocktails Present Efficacy, Manufacturing Tradeoffs

Ability to quickly scale manufacturing is a key criteria for Operation Warp Speed therapeutics, but for monoclonal antibodies the most effective approach may mean fewer doses. FDA’s Janet Woodcock said the government is supporting a range of antibody approaches for COVID-19 so that if virus escape mutants emerge from single antibody treatment there will be other options, while Regeneron argues the cocktail approach is safer, even though it will likely mean fewer doses of drug will be available.

Lilly CEO: Monoclonal Antibody Companies Should Share Coronavirus Manufacturing Capacity

David Ricks says a consortium of companies will be needed to ensure enough doses of the successful candidates are available.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel